Evidence map›Paper›PMID 29986747›Full record

ArticleJournal of ovarian research2018

Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).

Wei Jiang, Shuang Ye, Libing Xiang, Wentao Yang, Tiancong He, Xuan Pei, Lin Guo, Huijuan Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. AInternational journal of molecular sciences · 2023
    Article
  3. Harnessing preclinical models for the interrogation of ovarian cancer.Journal of experimental & clinical cancer research : CR · 2022
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wei JiangDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shuang YeDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Libing XiangDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Wentao YangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Tiancong HeDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xuan PeiDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lin GuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Huijuan YangDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. huijuanyang@hotmail.com.ORCID http://orcid.org/0000-0003-4569-6454
Shanghai Medical College of Fudan University · CN

Funding

National Natural Science Foundation of China 81572803National Natural Science Foundation of China 81702558
6 · The paper itself

Abstract

backgroundOvarian clear cell carcinoma is a distinct histologic subtype with grave survival. The underlying molecular mechanism is not fully elucidated. However, we don't have many cell lines, which are useful experimental tools for research. We describe the establishment and characterization of a new ovarian clear cell carcinoma cell line from a Chinese patient.

resultsFDOV1 has been subcultured for more than 80 generations. Monolayer cultured cells are polygonal in shape, showing a transparent cytoplasm full of vacuoles. The number of chromosomes ranges from 45 to 90. FDOV1 cells produces CA-125, but not CA-199. The cells could be transplanted and produced tumors mimicking the donor tumor morphologically and immunohistochemically. Whole exome sequence showed both FDOV1 and tissue block harbored PIK3CA H1047R mutation and ARID1A frameshift mutations (p.L2106 fs, p.N201 fs). More interestingly, we observed SPOP mutation (p.D82H) and ZNF217 (chromosome 20q13) amplification in FDOV1, which are quite novel.

conclusionsOnly a few patient-derived ovarian clear cell carcinoma cell lines have been reported in the literature. FDOV1 is the very first one, to the best of our knowledge, from a Mainland Chinese patient. It showed infinite multiplication until now and tumorigenicity in vivo. FDOV1 has co-existing PIK3CA and ARID1A mutations. It also harbored SPOP mutation and ZNF217 amplification, which would probably be a good model for exploring the molecular mechanism of ovarian clear cell carcinoma.

Indexed as

Cell Line, TumorAdenocarcinoma, Clear CellAnimalsBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFemaleGene AmplificationHeterograftsHumansMiceMutationNuclear ProteinsOvarian NeoplasmsRepressor ProteinsTrans-ActivatorsARID1A protein, humanBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsNuclear ProteinsPIK3CA protein, humanRepressor ProteinsSPOP protein, humanTrans-ActivatorsTranscription FactorsZNF217 protein, humanARID1ACell lineFDOV1Ovarian clear cell carcinomaPIK3CASPOPZNF217 amplification

Identifiers

PMID29986747
PMCPMC6038259
OpenAlexW2870249515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.